MedTrace Logo

A Phase IIb Study of AZD5462 in Patients With Chronic Heart Failure

NCT06299826 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 375

Last updated 2026-02-18

No results posted yet for this study

Summary

The main purpose of this study is to evaluate the effect of AZD5462 on cardiac function in participants with chronic heart failure (HF).

Conditions

Interventions

DRUG

Placebo

Participants will receive matching doses of film-coated tablets of Placebo OD orally.

DRUG

AZD5462

Participants will receive low, medium \& high doses of film-coated tablets of AZD5462 OD orally.

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-04
Primary Completion
2026-02-10
Completion
2026-02-10
FDA Drug
Yes

Countries

  • United States
  • Bulgaria
  • Czechia
  • Denmark
  • Hungary
  • India
  • Japan
  • Netherlands
  • Poland
  • Slovakia

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06299826 on ClinicalTrials.gov